243 related articles for article (PubMed ID: 15877529)
1. New opportunities in chemosensitization and radiosensitization: modulating the DNA-damage response.
Luo Y; Leverson JD
Expert Rev Anticancer Ther; 2005 Apr; 5(2):333-42. PubMed ID: 15877529
[TBL] [Abstract][Full Text] [Related]
2. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
[TBL] [Abstract][Full Text] [Related]
3. Targeted cancer therapies based on the inhibition of DNA strand break repair.
O'Connor MJ; Martin NM; Smith GC
Oncogene; 2007 Dec; 26(56):7816-24. PubMed ID: 18066095
[TBL] [Abstract][Full Text] [Related]
4. Poly(ADP-ribose) binding to Chk1 at stalled replication forks is required for S-phase checkpoint activation.
Min W; Bruhn C; Grigaravicius P; Zhou ZW; Li F; Krüger A; Siddeek B; Greulich KO; Popp O; Meisezahl C; Calkhoven CF; Bürkle A; Xu X; Wang ZQ
Nat Commun; 2013; 4():2993. PubMed ID: 24356582
[TBL] [Abstract][Full Text] [Related]
5. A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation.
Xiao Z; Xue J; Sowin TJ; Rosenberg SH; Zhang H
Oncogene; 2005 Feb; 24(8):1403-11. PubMed ID: 15608676
[TBL] [Abstract][Full Text] [Related]
6. Response of subtype-specific human breast cancer-derived cells to poly(ADP-ribose) polymerase and checkpoint kinase 1 inhibition.
Shibata H; Miuma S; Saldivar JC; Huebner K
Cancer Sci; 2011 Oct; 102(10):1882-8. PubMed ID: 21707865
[TBL] [Abstract][Full Text] [Related]
7. [PARP inhibitors: significant progress in cancer therapy].
Dantzer F; Noel G; Schreiber V
Bull Cancer; 2011 Mar; 98(3):277-90. PubMed ID: 21459712
[TBL] [Abstract][Full Text] [Related]
8. Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1.
Vance S; Liu E; Zhao L; Parsels JD; Parsels LA; Brown JL; Maybaum J; Lawrence TS; Morgan MA
Cell Cycle; 2011 Dec; 10(24):4321-9. PubMed ID: 22134241
[TBL] [Abstract][Full Text] [Related]
9. Role of poly(ADP-ribose) polymerase in cell-cycle checkpoint mechanisms following gamma-irradiation.
Masutani M; Nozaki T; Wakabayashi K; Sugimura T
Biochimie; 1995; 77(6):462-5. PubMed ID: 7578430
[TBL] [Abstract][Full Text] [Related]
10. Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1.
Veuger SJ; Curtin NJ; Richardson CJ; Smith GC; Durkacz BW
Cancer Res; 2003 Sep; 63(18):6008-15. PubMed ID: 14522929
[TBL] [Abstract][Full Text] [Related]
11. Poly(ADP-ribose) polymerase-1 protects excessive DNA strand breaks from deterioration during repair in human cell extracts.
Parsons JL; Dianova II; Allinson SL; Dianov GL
FEBS J; 2005 Apr; 272(8):2012-21. PubMed ID: 15819892
[TBL] [Abstract][Full Text] [Related]
12. How to kill tumor cells with inhibitors of poly(ADP-ribosyl)ation.
Mangerich A; Bürkle A
Int J Cancer; 2011 Jan; 128(2):251-65. PubMed ID: 20853319
[TBL] [Abstract][Full Text] [Related]
13. PARP inhibitors for cancer therapy.
Curtin NJ
Expert Rev Mol Med; 2005 Mar; 7(4):1-20. PubMed ID: 15836799
[TBL] [Abstract][Full Text] [Related]
14. Poly(ADP-ribose) polymerase-1 activation during DNA damage and repair.
Dantzer F; Amé JC; Schreiber V; Nakamura J; Ménissier-de Murcia J; de Murcia G
Methods Enzymol; 2006; 409():493-510. PubMed ID: 16793420
[TBL] [Abstract][Full Text] [Related]
15. Drug discovery targeting Chk1 and Chk2 kinases.
Zhou BB; Sausville EA
Prog Cell Cycle Res; 2003; 5():413-21. PubMed ID: 14593735
[TBL] [Abstract][Full Text] [Related]
16. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions.
D'Amours D; Desnoyers S; D'Silva I; Poirier GG
Biochem J; 1999 Sep; 342 ( Pt 2)(Pt 2):249-68. PubMed ID: 10455009
[TBL] [Abstract][Full Text] [Related]
17. Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets.
Chalmers AJ; Lakshman M; Chan N; Bristow RG
Semin Radiat Oncol; 2010 Oct; 20(4):274-81. PubMed ID: 20832020
[TBL] [Abstract][Full Text] [Related]
18. Progress in identifying clinical relevance of inhibition, stimulation and measurements of poly ADP-ribosylation.
Pero RW; Olsson A; Sheng Y; Hua J; Möller C; Kjellén E; Killander D; Marmor M
Biochimie; 1995; 77(5):385-93. PubMed ID: 8527494
[TBL] [Abstract][Full Text] [Related]
19. Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes.
Al-Ejeh F; Kumar R; Wiegmans A; Lakhani SR; Brown MP; Khanna KK
Oncogene; 2010 Nov; 29(46):6085-98. PubMed ID: 20818418
[TBL] [Abstract][Full Text] [Related]
20. YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors.
Stachelek GC; Peterson-Roth E; Liu Y; Fernandez RJ; Pike LR; Qian JM; Abriola L; Hoyer D; Hungerford W; Merkel J; Glazer PM
Mol Cancer Res; 2015 Oct; 13(10):1389-97. PubMed ID: 26116172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
